Advanced therapeutics across cell and gene therapy face multiple challenges to achieve regulatory clearance and clinical success, all within the tight time and cost limits of the drug development process.
Traditional approaches rely on viral or endogenous expression systems, often truncated to fit within vector size constraints, these compete with the transcriptional landscape of the cell, particularly where multiple vectors transduce the same cell, leading to complex downstream effects.
